Search

CN-121987645-A - Application of pedunculoside in preparation of medicine for treating psoriasis

CN121987645ACN 121987645 ACN121987645 ACN 121987645ACN-121987645-A

Abstract

The invention discloses application of ilexoside in preparing a medicament for treating psoriasis, and relates to the technical field of medicaments. The invention provides a natural candidate drug with definite structure, effectiveness and safety for clinical treatment of psoriasis.

Inventors

  • GAO HONGWEI
  • Yuan Ren Yi Kun
  • HUANG LITING

Assignees

  • 广西中医药大学

Dates

Publication Date
20260508
Application Date
20260204

Claims (10)

  1. 1. The use of ilexoside as the sole active ingredient in the manufacture of a medicament for the treatment of psoriasis.
  2. 2. The use according to claim 1, wherein the medicament comprises a therapeutically effective amount of pedunculoside and a pharmaceutically acceptable carrier.
  3. 3. The use of claim 2, wherein the pharmaceutically acceptable carrier comprises one or more of a diluent, a solvent, an emulsifier, a thickener, a humectant, a pH adjuster, and a preservative.
  4. 4. A use according to any one of claims 1 to 3, wherein the medicament is an external preparation selected from the group consisting of a cream, an ointment, a gel, a cream, a lotion or a patch.
  5. 5. The use according to claim 4, wherein the medicament is a cream comprising: a) An oil phase comprising stearic acid, glyceryl monostearate and castor oil; b) An aqueous phase comprising water, glycerol and triethanolamine, and C) Cosolvents, including 1, 2-propanediol.
  6. 6. The method according to claim 5, wherein the mass ratio of stearic acid, glyceryl monostearate and castor oil in the oil phase is 1 (0.2-0.5) (0.6-1.0).
  7. 7. The method according to claim 5, wherein the dosage ratio of glycerin, water and triethanolamine in the water phase is 1g (4.0-6.0) mL (0.1-0.2) mL.
  8. 8. The use according to claim 1, wherein the psoriasis is plaque psoriasis, spot psoriasis, arthrosis psoriasis or erythrodermic psoriasis.
  9. 9. The use according to claim 1, wherein the dosage of pedunculoside is not less than 0.8mg per administration.
  10. 10. The use of claim 1, wherein the agent down-regulates IL-17A and IFN- γ protein levels in skin tissue, inhibits expression levels of IL-6, IL-1 β, TNF- α, IL-17A, IL-22, and inhibits Th17 cell-mediated inflammatory factor levels.

Description

Application of pedunculoside in preparation of medicine for treating psoriasis Technical Field The invention relates to the technical field of medicines. More particularly, the invention relates to the use of pedunculoside as the sole active ingredient in the manufacture of a medicament for the treatment of psoriasis. Background Psoriasis is a chronic and recurrent inflammatory skin disease driven by genetic susceptibility and environmental factors, and takes abnormal proliferation and differentiation disorder of keratinocytes, vascular dilation of dermal papilla layers and immune inflammatory infiltration taking T cells/dendritic cells as cores as main pathological characteristics. Existing treatments include topical glucocorticoids and vitamin D analogues, phototherapy, systemic budesonide, methotrexate, cyclosporine, retinoids, biologicals and small molecule drugs targeting TNF- α, IL-17, IL-23. Although these drugs have a certain curative effect, the problems of high recurrence rate, immune suppression-related infection risk, hepatotoxicity, abnormal metabolism, high cost, insufficient response of partial patients or secondary tolerance and the like still exist in the long-term application process, in addition, the existing therapies are focused on suppressing a single inflammatory pathway, and the onset of psoriasis involves complex interactions of multiple immune inflammatory pathways, so that a certain difficulty exists in developing new therapeutic drugs with multiple regulatory effects and better safety. The ilex pedunculata glycoside (Pedunculoside, PE) is an active monomer component derived from holly bark, has pharmacological basis such as immunoregulation and the like, and has not been reported for treating psoriasis at present. Disclosure of Invention The invention provides an application of ilexoside as a unique active ingredient in preparing a medicament for treating psoriasis, and provides a natural candidate medicament with definite structure, effectiveness and safety for clinical treatment of psoriasis. To achieve these objects and other advantages and in accordance with the purpose of the invention, there is provided a use of ileside as the sole active ingredient in the preparation of a medicament for treating psoriasis. Preferably, the medicament comprises a therapeutically effective amount of ilexoside and a pharmaceutically acceptable carrier. Preferably, the pharmaceutically acceptable carrier includes one or more of a diluent, a solvent, an emulsifier, a thickener, a humectant, a pH adjuster, and a preservative. Preferably, the medicament is an external preparation selected from the group consisting of cream, ointment, gel, cream, lotion or patch. Preferably, the medicament is a cream comprising: a) An oil phase comprising stearic acid, glyceryl monostearate and castor oil; b) An aqueous phase comprising water, glycerol and triethanolamine, and C) Cosolvents, including 1, 2-propanediol. Preferably, the mass ratio of the stearic acid, the glyceryl monostearate and the castor oil in the oil phase is 1 (0.2-0.5) to 0.6-1.0. Preferably, the dosage ratio of the glycerol, the water and the triethanolamine in the water phase is 1g (4.0-6.0) mL (0.1-0.2) mL. It is preferred that the composition of the present invention, the psoriasis is plaque psoriasis psoriasis in the form of drops arthropathy-type psoriasis or erythrodermic-type psoriasis. Preferably, the administration dose of the pedunculoside is not less than 0.8mg each time. Preferably, the agent down regulates IL-17A and IFN-gamma protein levels in skin tissue, inhibits IL-6, IL-1 beta, TNF-alpha, IL-17A, IL-22 expression levels, and inhibits Th17 cell-mediated inflammatory factor levels. The invention at least comprises the following beneficial effects: Firstly, the invention takes the pedunculoside as the only active ingredient to prepare the medicine for treating psoriasis, and regulates and controls the release of inflammatory factors, inhibits abnormal immune activation and improves the inflammatory microenvironment of keratinocytes, thereby interfering the pathological closed loop formation of the immune imbalance-inflammatory amplification-epidermal hyperplasia of the psoriasis and taking the effectiveness and the safety into account. Secondly, the pedunculoside can inhibit the expression of a plurality of key inflammatory factors such as IL-17A, IFN-gamma and the like, inhibit the level of inflammatory factors mediated by Th17 cells, has a comprehensive and accurate action mechanism, covers the core links of psoriasis onset, can more comprehensively inhibit inflammatory reaction, improve abnormal hyperplasia of epidermis, promote treatment effect and reduce repeated risks of illness compared with partial single targeted drugs. Additional advantages, objects, and features of the invention will be set forth in part in the description which follows and in part will become apparent to those having ordinary skill in the art upon